AngioDynamics Earnings Call Transcripts
Fiscal Year 2026
-
The company has transformed its portfolio, focusing on high-growth MedTech segments and innovative devices for cardiovascular and oncology markets. Strong financials, ongoing product innovation, and market expansion position it for sustained growth and margin improvement.
-
Third quarter revenue grew 8.9% year-over-year, led by MedTech segment strength and robust growth in Auryon, AlphaVac, and NanoKnife. Full-year guidance for net sales and adjusted EBITDA was raised for the third consecutive quarter, with strong cash and no debt.
-
The business has transformed into a tech-focused med tech company, driving strong growth in cardiovascular and oncology platforms. Med Tech products are outperforming expectations, with Auryon and AlphaVac leading expansion, while NanoKnife is gaining traction in prostate cancer and BPH. Robust R&D and a growing sales force support continued momentum.
-
A science-driven transformation has positioned the company for strong growth, with MedTech now driving over 45% of revenue and expanding rapidly. Key products like Auryon, AlphaVac, and NanoKnife are gaining market share, while financial performance is improving with positive EBITDA and cash flow. Leadership transition is underway, but the outlook remains robust.
-
Revenue grew 8.8% year-over-year, led by Med Tech and Auryon platform strength, with gross margin up 170 bps and adjusted EBITDA nearly doubling. Full-year guidance for revenue and EBITDA was raised, and key regulatory milestones were achieved in mechanical thrombectomy. Leadership transition was announced.
-
Revenue grew 12.2% year-over-year to $75.7 million, led by 26% med-tech growth and strong gains in mechanical thrombectomy and NanoKnife. Gross margin improved to 55.3%, and guidance for fiscal 2026 was raised, reflecting confidence in continued segment momentum.
Fiscal Year 2025
-
A focused MedTech strategy has driven strong growth, with the MedTech segment now nearing half of total revenue and expected to become the largest segment. Key platforms in oncology, PAD, and thrombectomy are expanding through innovation and clinical data, supporting double-digit growth and margin expansion.
-
A company in transformation is driving double-digit growth in Med Tech by focusing on innovative cardiovascular and oncology solutions, expanding its addressable market, and achieving positive EBITDA and cash flow. Key products like AlphaVac, Auryon, and NanoKnife are set for continued growth in FY 2026.
-
Q4 revenue grew 12.7% year-over-year, led by MedTech up 22%, with strong gains in Auryon and mechanical thrombectomy. FY 2026 guidance projects 4–6% revenue growth, continued MedTech momentum, and positive cash flow despite tariff headwinds.
-
Significant portfolio transformation has positioned the business as a leader in cardiovascular innovation, with Auryon and AlphaVac platforms driving growth in large, high-margin markets. Strong clinical evidence, ongoing product enhancements, and strategic expansion into new indications underpin future growth.
-
Third quarter revenue grew 9% year-over-year to $72 million, led by 22% med tech growth and strong performance in Auryon, AlphaVac, and AngioVac. Guidance for fiscal 2025 was raised across revenue, gross margin, and adjusted EBITDA, with continued focus on high-growth med tech markets.
-
A multi-year transformation has shifted focus to high-growth med tech platforms in cardiovascular and oncology, with strong clinical, regulatory, and financial milestones achieved. Positive EBITDA, expanding gross margins, and new product launches position the company for sustained, profitable growth.
-
NanoKnife’s FDA approval and robust clinical data position it for rapid adoption in the growing prostate cancer market. The technology’s unique mechanism, ease of integration, and strong patient outcomes support a scalable revenue model, with regulatory and reimbursement milestones driving both U.S. and global expansion.
-
Revenue grew 9% year-over-year to $73M, led by 25% Med Tech growth and strong thrombectomy performance. Adjusted EBITDA turned positive, and guidance was raised for Med Tech sales and profitability. Manufacturing transition and new product clearances support long-term growth.
-
Q1 revenue grew 1.1% to $67.5M, led by MedTech and strong Auryon/AlphaVac growth. Adjusted EBITDA loss narrowed, and guidance for FY25 was reiterated. Key catalysts included new product launches, regulatory milestones, and a manufacturing transition targeting $15M in annual savings.
Fiscal Year 2024
-
Transformation to a high-growth med tech focus is driving margin expansion and global market access, with Auryon, AlphaVac, and NanoKnife as key growth drivers. FY25 guidance targets 4.2%-6.2% growth, and gross margins are set to rise post-manufacturing shift.
-
Q4 revenue grew 2% YoY to $71.1M, with Med Tech up 11% and strong growth in Auryon and NanoKnife. FY25 guidance projects 4.2%–6.4% revenue growth, 10%–12% Med Tech growth, and continued margin pressure from manufacturing transition.